PE20211471A1 - Formulacion de medios de contraste y proceso para prepararlos - Google Patents

Formulacion de medios de contraste y proceso para prepararlos

Info

Publication number
PE20211471A1
PE20211471A1 PE2021000733A PE2021000733A PE20211471A1 PE 20211471 A1 PE20211471 A1 PE 20211471A1 PE 2021000733 A PE2021000733 A PE 2021000733A PE 2021000733 A PE2021000733 A PE 2021000733A PE 20211471 A1 PE20211471 A1 PE 20211471A1
Authority
PE
Peru
Prior art keywords
metal ion
paramagnetic metal
alkyl
formulation
group
Prior art date
Application number
PE2021000733A
Other languages
English (en)
Inventor
Stephan Holzschuh
Thomas Frenzel
Gregor Jost
Jessica Lohrke
Wolfgang Ebert
Thomas Brumby
Wolfgang Halfbrodt
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of PE20211471A1 publication Critical patent/PE20211471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La presente divulgacion se refiere a una formulacion farmaceutica liquida que comprende un tetra-quelato derivado de DO3A de la formula general (I), donde R1 representa un grupo seleccionado de a), b) o c); indica el punto de union de dicho grupo con el resto de la molecula; R2, R3 y R4 son hidrogeno, alquilo-C1-C6, cicloalquilo-C3-C6, (alcoxi-C1-C2)-(alquil-C2-C3)-, fenilo; entre otros; R5 es alquilo-C1-C6, cicloalquilo-C3-C6, (alcoxi-C1-C2)-(alquil-C2-C3)-, fenilo, entre otros; X representa un grupo C(=O)OH o C(=O)O- y M representa un ion de un metal paramagnetico. El tetra-quelato derivado de DO3A tiene una concentracion en la formulacion en un intervalo de 1 a 1000 mmol de ion metalico paramagnetico/L y el ion del metal paramagnetico no es Gd3+, y en un intervalo de 60 a 750 mmol de ion metalico paramagnetico/L, en donde el ion del metal paramagnetico tambien puede ser Gd3+. Dichas formulaciones son utiles como agentes de contraste, en particular para imagenes de resonancia magnetica.
PE2021000733A 2018-11-23 2019-11-21 Formulacion de medios de contraste y proceso para prepararlos PE20211471A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18208090 2018-11-23
PCT/EP2019/082117 WO2020104602A1 (en) 2018-11-23 2019-11-21 Formulation of contrast media and process of preparation thereof

Publications (1)

Publication Number Publication Date
PE20211471A1 true PE20211471A1 (es) 2021-08-05

Family

ID=64456867

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000733A PE20211471A1 (es) 2018-11-23 2019-11-21 Formulacion de medios de contraste y proceso para prepararlos

Country Status (16)

Country Link
US (1) US11944690B2 (es)
EP (1) EP3883613A1 (es)
JP (1) JP2022508185A (es)
KR (1) KR20210095168A (es)
CN (1) CN113164628A (es)
AU (1) AU2019382881A1 (es)
BR (1) BR112021007707A2 (es)
CA (1) CA3120665A1 (es)
CL (2) CL2021001331A1 (es)
CO (1) CO2021006034A2 (es)
IL (1) IL283281A (es)
JO (1) JOP20210114A1 (es)
MX (1) MX2021006024A (es)
PE (1) PE20211471A1 (es)
SG (1) SG11202104657RA (es)
WO (1) WO2020104602A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4335461A1 (en) * 2022-09-09 2024-03-13 Bayer AG Combinations of contrast agents
EP4360660A1 (en) * 2022-10-24 2024-05-01 Bayer AG Process for the preparation of a gadolinium contrast agent

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
US4485237A (en) 1983-03-08 1984-11-27 The United States Of America As Represented By The Secretary Of The Navy Insensitive polynitramine compound
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5039512A (en) 1986-08-04 1991-08-13 Salutar, Inc. NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5138923A (en) 1988-11-18 1992-08-18 Atlas Die, Inc. Rotary die cutter
US5011925A (en) 1989-03-09 1991-04-30 Mallinckrodt, Inc. Morpholinoamido EDTA derivatives
DE69032761T2 (de) 1989-08-28 1999-04-22 Gen Hospital Corp Hydroxy-aryl metallchelate für bildformung zur nmr diagnose
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
GB9320277D0 (en) 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
SG49726A1 (en) 1989-10-23 1998-06-15 Nycomed Salutar Inc Compounds
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US5167942A (en) 1990-11-21 1992-12-01 Board Of Regents, The University Of Texas System Methods for the preparation of molecular sieves, including zeolites, using metal chelate complexes
AU656355B2 (en) 1990-11-21 1995-02-02 Mallinckrodt Medical, Inc. Alkoxyamide derivatized chelates for MRI
US5141740A (en) 1990-11-21 1992-08-25 Mallinckrodt Medical, Inc. Complexes and compositions for magnetic resonance imaging and usage methods
JPH06507174A (ja) 1991-04-22 1994-08-11 マリンクロッド・メディカル・インコーポレイテッド ニューロキニン１レセプターを有する組織を検出および局部化する方法
CA2102605A1 (en) 1991-05-23 1992-11-24 Evan C. Unger Liposoluble compounds for magnetic resonance imaging
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
WO1993011120A1 (en) 1991-11-27 1993-06-10 Zynaxis Technologies, Incorporated Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
AU3415493A (en) 1991-12-10 1993-07-19 Dow Chemical Company, The Bicycle-polyazamacrocyclocarboxylic acid complexes, conjugates, preparation and use as contrast agents
US5324503A (en) 1992-02-06 1994-06-28 Mallinckrodt Medical, Inc. Iodo-phenylated chelates for x-ray contrast
DE4232925A1 (de) 1992-09-28 1994-03-31 Diagnostikforschung Inst 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
ATE195432T1 (de) 1993-06-02 2000-09-15 Bracco Spa Iodierte paramagnetische chelaten, und deren verwendung als kontrastmittel
IT1264690B1 (it) 1993-07-08 1996-10-04 Bracco Spa Compositi oligomeri iodurati e composizioni diagnostiche contenenti gli stessi
AU1694895A (en) 1994-01-28 1995-08-15 Mallinckrodt Medical, Inc. Functionalized aza-bimacrocyclic ligands for imaging applications
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE4425857A1 (de) 1994-07-07 1996-01-11 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel
IL115670A (en) 1994-10-21 1999-11-30 Nihon Mediphysics Co Ltd Diagnostic imaging agent
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
DE19525924A1 (de) 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
DE19549286A1 (de) 1995-12-22 1997-06-26 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE19603033A1 (de) 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19608278A1 (de) 1996-02-23 1997-08-28 Schering Ag Pharmazeutische Mittel enthaltend perfluoralkylhaltige Metallkomplexe, und ihre Verwendung in der Tumortherapie und interventioniellen Radiologie
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US5866562A (en) 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
US6045776A (en) 1996-12-04 2000-04-04 Schering Aktiengesellschaft Process for the production of metal-complex carboxylic acid amides
DE19652386A1 (de) 1996-12-04 1998-06-10 Schering Ag Verfahren zur Herstellung von Metallkomplexcarbonsäureamiden
US5919433A (en) 1996-12-04 1999-07-06 Schering Aktiengesellschaft Macrocyclic metal complex carboxylic acids, their use as well as process for their production
DE19652387A1 (de) 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
DE19729013A1 (de) 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
DE19744003B4 (de) 1997-09-26 2004-07-08 Schering Ag Kontrastmittel für das Infarkt- und Nekroseimaging
DE69811931T2 (de) 1997-10-27 2003-12-18 Res Corp Technologies Inc Mri-mittel für die verabreichung von therapeutischen mitteln
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
DE19831217A1 (de) 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
EP0998946A1 (en) 1998-08-14 2000-05-10 K.U. Leuven Research & Development Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6232265B1 (en) 1999-06-11 2001-05-15 Ibc Advanced Technologies, Inc. Particulate solid supports functionalized with polyhydroxypyridinone ligands
US6221476B1 (en) 1999-06-11 2001-04-24 Ibc Advanced Technologies, Inc. Polymeric membranes functionalized with polyhydroxypyridinone ligands
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
EP1088559A3 (de) 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Galenische Formulierungen
DE19948651B4 (de) 1999-09-29 2006-10-05 Schering Ag Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
JP2003520255A (ja) 2000-01-22 2003-07-02 エピックス メディカル， インコーポレイテッド 酵素的な切断によって生理活性化される造影剤プロドラッグを使用した磁気共鳴画像法
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
IT1317862B1 (it) 2000-02-29 2003-07-15 Bracco Spa Coniugati di acidi biliari con chelati complessi di ioni metallici eloro uso.
WO2001097860A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
ATE414541T1 (de) 2000-06-21 2008-12-15 Lantheus Medical Imaging Inc Vitronectin rezeptor antagonist pharmaka
DE10040858C2 (de) 2000-08-11 2003-12-18 Schering Ag Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung
DE10066210B4 (de) 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
DE10040381C1 (de) 2000-08-11 2002-06-06 Schering Ag Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung
IL145723A0 (en) 2000-10-11 2002-07-25 Nihon Mediphysics Co Ltd Process for producing an amide compound
US20030050452A1 (en) 2000-12-26 2003-03-13 Yuji Hashiguchi Process for producing metal complex of aminooligosaccharide derivative
US20030004236A1 (en) 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
ITMI20011708A1 (it) 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
FR2836916B1 (fr) 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
US20030198597A1 (en) 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
DE10231799B4 (de) 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20060155120A1 (en) 2003-05-23 2006-07-13 Amedio John C Optically pure and enriched isomers of chelating ligands and contrast agents
AR047692A1 (es) 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
DE102004023093B3 (de) 2004-05-05 2006-03-02 Schering Ag Trimere makrocyclisch substituierte Halogen-Benzolderivate
DE102004026103A1 (de) 2004-05-25 2005-12-22 Schering Ag Trimere makrocyclisch substituierte Aminoisophthalsäure-Halogen-Benzolderivate
WO2006002875A1 (en) 2004-07-02 2006-01-12 Bracco Imaging Spa Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
WO2006014530A2 (en) 2004-07-07 2006-02-09 The General Hospital Corporation Imaging of enzyme activity
US20060057071A1 (en) 2004-09-14 2006-03-16 Wing-Tak Wong Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as MRI contrast agents
US7205385B2 (en) 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
US20080305049A1 (en) 2005-01-31 2008-12-11 Hadassa Degani Mri Contrast Agents for Diagnosis and Prognosis of Tumors
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
ATE534407T1 (de) 2005-12-01 2011-12-15 Ge Healthcare As Verfahren zur dynamischen kernpolarisation (dnp) unter verwendung eines tritylrests und eines paramagnetischen metallions
AU2006321058B2 (en) 2005-12-02 2012-06-28 Ge Healthcare As Multimeric magentic resonance contrast agents
EP1962912B1 (en) 2005-12-16 2012-09-26 Ge Healthcare As Method to produce hyperpolarised carboxylates of organic amines
US20080058636A1 (en) 2005-12-29 2008-03-06 Epix Pharmaceuticals, Inc. Methods of myocardial imaging
US20070202047A1 (en) 2006-01-05 2007-08-30 Markus Wolf Polyamine-substituted ligands for use as contrast agents
EP1815870A1 (en) 2006-02-01 2007-08-08 DKFZ Deutsches Krebsforschungszentrum Cyanine dye compounds linked to metal chelator for bi-modal diagnostic imaging
KR20080099279A (ko) 2006-02-24 2008-11-12 말린크로트, 인코포레이티드 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트
US8252778B2 (en) 2006-03-24 2012-08-28 University Of Utah Research Foundation Highly fluorinated oils and surfactants and methods of making and using same
US20090110640A1 (en) 2006-03-29 2009-04-30 Oskar Axelsson Contrast agents for magnetic resonance imaging and spectroscopy consisting of a cyclic oligoamid core of 3 to 4 identicial monomer units with 3 to 4 paramagnetic chelate side chains
EP1998813A2 (en) 2006-03-29 2008-12-10 GE Healthcare AS Method to produce hyperpolarised carboxylates and sulphonates in the presence of inorganic cations
WO2007128873A1 (en) 2006-05-05 2007-11-15 Wallac Oy A method for the preparation of maleimido derivatives of biomolecule labeling reactants and conjugates derived thereof
DE102006021495A1 (de) 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
JP2008012596A (ja) 2006-07-03 2008-01-24 Aji Kk 把持装置
US9127130B2 (en) 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
JP5563299B2 (ja) 2006-08-17 2014-07-30 エピックス ファーマシューティカルズ，インコーポレイテッド リンパ系撮像方法
DE102007002726A1 (de) 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
WO2009013350A2 (en) 2007-07-26 2009-01-29 Ge Healthcare Uk Limited Imaging medium comprising hyperpolarised 13 c-lactate and use thereof
WO2009018332A1 (en) 2007-08-01 2009-02-05 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
ATE534408T1 (de) 2007-08-27 2011-12-15 Ge Healthcare Ltd Bildgebungsmedium mit hyperpolarisiertem uüc- acetat und seine verwendung
AU2008294727B2 (en) 2007-09-07 2013-10-17 Ge Healthcare Limited Method of determination of PDH activity and imaging media for use in said method
FR2921929B1 (fr) 2007-10-08 2013-01-11 Commissariat Energie Atomique Procede de preparation de materiaux polymeriques dopes par des elements metalliques et materiaux obtenus par ce procede
DE102007058220A1 (de) 2007-12-03 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Dimere macrocyclisch substituierte Benzolderivate
EP2072061A1 (en) 2007-12-19 2009-06-24 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
WO2009080739A1 (en) 2007-12-21 2009-07-02 Ge Healthcare Limited Mr imaging agent, imaging medium and methods of imaging wherein such an imaging medium is used
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
US8545813B2 (en) 2008-01-25 2013-10-01 Northwestern University Pre-templated macromolecular architectures with multiple Gd(III) complexes and methods of use as MRI contrast agents
JP2011514313A (ja) 2008-02-04 2011-05-06 ジーイー・ヘルスケア・リミテッド 過分極アミノ酸及びアミノスルホン酸の製造方法
CN101932341A (zh) 2008-02-04 2010-12-29 通用电气健康护理有限公司 Mr成像剂或包含超极化13c-丙氨酸的成像介质和使用该成像介质的成像方法
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
EP2279190A1 (en) 2008-04-18 2011-02-02 Ge Healthcare As Compounds comprising paramagnetic chelates arranged around a central core and their use in magneto resonance imaging and spectroscopy
JP2011520971A (ja) 2008-05-19 2011-07-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ ガストリン放出ペプチド化合物
EP2149567A1 (en) 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
US8858916B2 (en) 2008-09-30 2014-10-14 Mallinckrodt Llc Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent
WO2010056590A2 (en) 2008-11-14 2010-05-20 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
FR2939318B1 (fr) 2008-12-10 2012-07-13 Guerbet Sa Systeme d'encapsulation pour imagerie cest avec quelate q superieur ou egal a 2
WO2010108125A2 (en) 2009-03-19 2010-09-23 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US20110081428A1 (en) 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
DE102009053171B4 (de) * 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
WO2011088193A2 (en) 2010-01-13 2011-07-21 University Of Medicine And Dentistry Of New Jersey Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
EP2555803B1 (en) 2010-04-08 2018-09-12 Bracco Imaging S.p.A Process for preparing hyperpolarized substrates and method for mri
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
EP2457594A1 (en) 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
US9011816B2 (en) 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
EP2699272A4 (en) 2011-04-20 2014-10-15 Rf Therapeutics Inc CONTRAST AGENTS AND USES THEREOF
KR102003570B1 (ko) 2011-04-21 2019-07-24 바이엘 인텔렉쳐 프로퍼티 게엠베하 고순도 가도부트롤의 제조
US8926944B2 (en) 2011-08-05 2015-01-06 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
CN102973955B (zh) 2011-09-06 2016-03-23 中国科学院福建物质结构研究所 一种含三价铝的磁共振成像造影剂
CN102442996B (zh) 2011-09-16 2014-09-24 中山大学附属第一医院 多胺类小分子显像剂、其生产方法及其应用
ES2414291B2 (es) 2011-12-16 2014-02-13 Universitat De Valencia Compuestos macrocíclicos de tipo escorpiando y su uso como antiparasitarios.
KR101336071B1 (ko) 2012-01-04 2013-12-05 한국원자력의학원 암 진단용 ｍｒｉ／ｃｔ 이중 조영제 및 그 제조방법
CN102614531B (zh) 2012-04-06 2013-06-05 中国科学院长春应用化学研究所 以二乙酰基苯或三乙酰基苯为连接体的多核非离子型磁共振成像造影剂
US9585975B2 (en) 2012-04-27 2017-03-07 Northwestern University MRI contrast agents
KR101456234B1 (ko) 2012-08-09 2014-11-04 한국원자력의학원 아미노시클로헥산카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｍｒｉ 조영제
KR101456233B1 (ko) 2012-08-09 2014-11-04 한국원자력의학원 아미노시클로펜탄카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｍｒｉ 조영제
KR102190005B1 (ko) 2012-09-25 2020-12-15 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드. Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
WO2014075079A1 (en) 2012-11-12 2014-05-15 The General Hospital Corporation Peptidic structures incorporating an amino acid metal complex and applications in magnetic resonance imaging
SG11201505477TA (en) 2013-01-14 2015-08-28 Molecular Insight Pharm Inc Triazine based radiopharmaceuticals and radioimaging agents
CA2900595A1 (en) 2013-02-12 2014-08-21 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
PL2988756T5 (pl) 2013-04-26 2022-09-26 Guerbet Formulacja środka kontrastowego i powiązany sposób jego wytwarzania
WO2014197763A1 (en) 2013-06-07 2014-12-11 The Board Of Regents Of The University Of Teas System Molecular design toward dual-modality probes for radioisotope-based imaging (pet or spect) and mri
CN103554185A (zh) 2013-07-04 2014-02-05 上海工程技术大学 一类大环多胺类多齿配体及其合成方法
EP2873679A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
CN103611171B (zh) 2013-11-25 2015-03-25 中国科学院长春应用化学研究所 以四苯酰基甲烷为连接体的非离子型多核磁共振成像造影剂及其制备方法
JP6749249B2 (ja) 2014-05-06 2020-09-02 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤
WO2016050210A1 (zh) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物及其制备方法
US20180221513A1 (en) 2015-03-16 2018-08-09 Northwestern University Contrast-agent-labeled peptide amphiphile nanofibers
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20160375155A1 (en) 2015-06-29 2016-12-29 Collagen Medical, LLC Collagen Imaging Compositions
WO2017030728A1 (en) 2015-08-17 2017-02-23 Southwestern Oklahoma State University Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same
EP3383441A1 (en) 2015-11-30 2018-10-10 GE Healthcare AS Formulations comprising a combination of mri contrast agents
DK3753929T3 (da) 2015-12-10 2023-01-23 Bracco Imaging Spa Dimere kontrastmidler
CN108290849B (zh) 2015-12-10 2022-03-22 伯拉考成像股份公司 造影剂
US10656229B2 (en) 2016-04-06 2020-05-19 Northwestern University Magnetic barcode imaging
WO2017178301A1 (en) 2016-04-13 2017-10-19 Bracco Imaging Spa Contrast agents
CA3044877A1 (en) * 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CA3037803A1 (en) 2016-12-12 2018-06-21 Bracco Imaging Spa Dimeric contrast agents

Also Published As

Publication number Publication date
WO2020104602A1 (en) 2020-05-28
SG11202104657RA (en) 2021-06-29
JP2022508185A (ja) 2022-01-19
US20220008562A1 (en) 2022-01-13
CO2021006034A2 (es) 2021-05-20
KR20210095168A (ko) 2021-07-30
CL2021001331A1 (es) 2021-10-22
JOP20210114A1 (ar) 2023-01-30
IL283281A (en) 2021-07-29
BR112021007707A2 (pt) 2021-07-27
CA3120665A1 (en) 2020-05-28
CN113164628A (zh) 2021-07-23
EP3883613A1 (en) 2021-09-29
CL2023003162A1 (es) 2024-04-01
MX2021006024A (es) 2021-07-06
US11944690B2 (en) 2024-04-02
AU2019382881A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
EA201891841A1 (ru) 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
AR095342A1 (es) Piridinas 2,3-sustituidas y su uso para la modulación de hemoglobina
DOP2015000239A (es) Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores del bromodominio
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
BR112015015216A2 (pt) composto de tetrazolinona e uso do mesmo
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
CL2017000804A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR088449A1 (es) Benzilindazoles sustituidos
PE20211471A1 (es) Formulacion de medios de contraste y proceso para prepararlos
DOP2013000088A (es) Barra de refuerzo y método para fabricar la misma
AR095341A1 (es) Compuestos y usos para la modulación de hemoglobina
ES2663948T3 (es) Moduladores de TGR5 y método de uso de los mismos
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
CU20170155A7 (es) Un compuesto de quelato de gadolinio, un proceso para usar su preparación y compuestos intermediarios para la preparación del mismo
CL2023002723A1 (es) Nuevo agente de contraste para utilizar en imágenes por resonancia magnética
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
AR068912A1 (es) Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
PE20160801A1 (es) Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos
MY182549A (en) Ether compounds and related compositions
IN2014DN05818A (es)
CO2018010787A2 (es) Compuesto de griseofulvina
AR072301A1 (es) Derivados de acido fenoxicroman carboxilico 6-sustituido utiles en el tratamiento y/o prevencion de enfermedades alergicas e inflamatorias, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos y compuestos intermediarios.